Oxaliplatin and/or gemcitabine vs. FOLFIRINOX in first-line Advanced pancreatic adenocarcinoma: Real-world efficacy and safety data of moroccan patients
Background: While fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) offers a survival advantage in advanced pancreatic adenocarcinoma (PAC) compared to gemcitabine, gemcitabine-oxaliplatin, and gemcitabine-nab-paclitaxel, the outcome of these regimens in African countries is still i...
Furkejuvvon:
| Váldodahkkit: | , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Elsevier
2025-01-01
|
| Ráidu: | Cancer Treatment and Research Communications |
| Fáttát: | |
| Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S2468294225001728 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|